Cited by 544Diabetes Treatment and ManagementBone health and osteoporosis researchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record, with a small difference in title or year; 24 of the 24 references it cites were found in a registry or an index.

Rosiglitazone-Associated Fractures in Type 2 Diabetes

Open access

Kahn, Steven E., Zinman, Bernard, Lachin, John M., Haffner, Steven M., Herman, William H., Holman, Rury R., Kravitz, Barbara G., Yu, Dahong, Heise, Mark A., Aftring, R. Paul, Viberti, Giancarlo, for the A Diabetes Outcome Progression Trial (ADOPT) Study Group·2008·Diabetes Care

DOI 10.2337/dc07-2270

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE—The purpose of this study was to examine possible factors associated with the increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). RESEARCH DESIGN AND METHODS—Data from the 1,840 women and 2,511 men randomly assigned in ADOPT to rosiglitazone, metformin, or glyburide for a median of 4.0 years were examined with respect to time to first fracture, rates of occurrence, and sites of fractures. RESULTS—In men, fracture rates did not differ between treatment groups. In women, at least one fracture was reported with rosiglitazone in 60 patients (9.3% of patients, 2.74 per 100 patient-years), metformin in 30 patients (5.1%, 1.54 per 100 patient-years), and glyburide in 21 patients (3.5%, 1.29 per 100 patient-years). The cumulative incidence (95% CI) of fractures in women at 5 years was 15.1% (11.2–19.1) with rosiglitazone, 7.3% (4.4–10.1) with metformin, and 7.7% (3.7–11.7) with glyburide, representing hazard ratios (95% CI) of 1.81 (1.17–2.80) and 2.13 (1.30–3.51) for rosiglitazone compared with metformin and glyburide, respectively. The increase in fractures with rosiglitazone occurred in pre- and postmenopausal women, and fractures were seen predominantly in the lower and upper limbs. No particular risk factor underlying the increased fractures in female patients who received rosiglitazone therapy was identified. CONCLUSIONS—Further investigation into the risk factors and underlying pathophysiology for the increased fracture rate in women taking rosiglitazone is required to relate them to preclinical data and better understand the clinical implications of and possible interventions for these findings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dc07-2270

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citation
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U., Kubota, N., Terauchi, Y., Harada, Y., Azuma, Y., Nakamura, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19900 · Cited by 869
Older Women with Diabetes Have an Increased Risk of Fracture: A Prospective Study
Schwartz, A. V., Sellmeyer, D. E., Ensrud, K. E., Cauley, J. A., Tabor, H. K., Schreiner, P. J., Jamal, S. A., Black, D. M., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7139 · Cited by 788
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419900 · Cited by 730
Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study.
Bonds, D., Larson, J. C., Schwartz, A., Strotmeyer, E., Robbins, J. A., Rodríguez, B., Johnson, K. C., & Margolis, K. (2006) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2006-0614 · Cited by 602
Type 1 and Type 2 Diabetes and Incident Hip Fractures in Postmenopausal Women
Nicodemus, K. K., & Folsom, A. R. (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1192 · Cited by 569
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka‐Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L. D., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 499
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.
Lecka‐Czernik, B., Gubrij, I. B., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · PubMed · Cited by 464
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Rzońca, S., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka‐Czernik, B. (2003) · Endocrinology · doi:10.1210/en.2003-0746 · Cited by 455
Rosiglitazone Causes Bone Loss in Mice by Suppressing Osteoblast Differentiation and Bone Formation
Ali, A., Weinstein, R. S., Stewart, S. A., PARFITT, A. M., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2004-0735 · Cited by 444

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 1

Snedecor GW, Cochran WG: Statistical Methods. 7th ed. Ames, Iowa, Iowa State University Press, 1980

Sorted by citations

Items 301–400 of 544

Glucose-Lowering Drugs and Fracture Risk—a Systematic Review
Al-Mashhadi, Z. K., Viggers, R., Fuglsang-Nielsen, R., de Vries, F., van den Bergh, J. P., Harsløf, T., Langdahl, B. L., Gregersen, S., & Starup‐Linde, J. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00638-8 · Cited by 18
Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel
Chiodini, I., Gaudio, A., Palermo, A., Napoli, N., Vescini, F., Falchetti, A., Merlotti, D., Eller-Vainicher, C., Carnevale, V., Scillitani, A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.014 · Cited by 18
Islet cell dysfunction in patients with chronic pancreatitis
Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Pottakkat, B. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i7.280 · Cited by 17
A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
Kim, B., Kwon, H., Kim, S. K., Noh, J.-H., Park, H.-K., Park, H.-K., Song, K.-H., Won, J. C., Yu, J. M., Lee, J. H., et al. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0264 · Cited by 17
AHRQ’s Comparative Effectiveness Research on Oral Medications for Type 2 Diabetes: A Summary of the Key Findings
Bennett, W. L., Balfe, L. M., & Faysal, J. M. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s1-a.1 · Cited by 17
Synthesis and biological evaluation of novel (−)-cercosporamide derivatives as potent selective PPARγ modulators
Furukawa, A., Arita, T., Fukuzaki, T., Mori, M., Honda, T., Satoh, S., Matsui, Y., Wakabayashi, K., Hayashi, S., Nakamura, K., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.05.040 · Cited by 17
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
Simonson, G., Cuddihy, R. M., Reader, D., & Bergenstal, R. M. (2011) · Diabetes Management · doi:10.2217/dmt.10.22 · Cited by 17
Effect of the antidiabetic agent pioglitazone on bone metabolism in rats
Kanda, J., Izumo, N., Kobayashi, Y., Onodera, K., Shimakura, T., Yamamoto, N., Takahashi, H. E., & Wakabayashi, H. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.08.004 · Cited by 17
Incident Type 2 Diabetes and Risk of Fracture: A Comparative Cohort Analysis Using U.K. Primary Care Records
Davie, G. S., Pal, K., Orton, E., Tyrrell, E. G., & Petersen, I. (2020) · Diabetes Care · doi:10.2337/dc20-1220 · Cited by 17
Are the adverse effects of glitazones linked to induced testosterone deficiency?
Carruthers, M. E., Trinick, T., Jankowska, E. A., & Traish, A. M. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-30 · Cited by 19
Substituents at the naphthalene C3 position of (−)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists
Furukawa, A., Arita, T., Fukuzaki, T., Satoh, S., Mori, M., Honda, T., Matsui, Y., Wakabayashi, K., Hayashi, S., Araki, K., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.066 · Cited by 16
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial
Bertrand, O. F., Poirier, P., Rodés‐Cabau, J., Rinfret, S., Title, L. M., Džavík, V., Natarajan, M. K., Angel, J. G. D., Batalla, N., Alméras, N., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70136-9 · Cited by 16
Prevention and management of transplant-associated diabetes
Jenssen, T. G., & Hartmann, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.628936 · Cited by 16
The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes
Xiao, W., Wang, Y., Hou, W., Xie, C., Wang, H., Hong, T., & Gao, H. (2013) · International Journal of Endocrinology · doi:10.1155/2013/290734 · Cited by 16
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US
Lee, W. C., Conner, C., & Hammer, M. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.559444 · Cited by 16
Effects of anti-diabetic drugs on bone metabolism
Mabilleau, G., Chappard, D., Flatt, P. R., & Irwin, N. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1077697 · Cited by 16
Impact of Incretin Therapy on Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes
McGill, J. B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.01.1954 · Cited by 15
Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations
Home, P. (2013) · Diabetes Care · doi:10.2337/dc12-2449 · Cited by 15
Chronic Pancreatitis and Diabetes Mellitus
Lin, Y. K., Johnston, P. C., Arce, K. M., & Hatipoğlu, B. (2015) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-015-0055-x · Cited by 17
Lack of Adiponectin Drives Hyperosteoclastogenesis in Lipoatrophic Mice
Madel, M., Fu, H., Pierroz, D. D., Schiffrin, M., Winkler, C., Wilson, A., Pochon, C., Toffoli, B., Taieb, M., Jouzeau, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.627153 · Cited by 15
Continuous subcutaneous insulin infusion ameliorates bone structures and mechanical properties in type 2 diabetic rats by regulating bone remodeling
Shi, P., Hou, A., Li, C., Wu, X., Jia, S., Cen, H., Hu, X., & Gong, H. (2021) · Bone · doi:10.1016/j.bone.2021.116101 · Cited by 14
Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors
Byreddy, D. V., Bouchonville, M. F., & Lewiecki, E. M. (2015) · Climacteric · doi:10.3109/13697137.2015.1103615 · Cited by 14
Cultured Human Periosteal-Derived Cells Have Inducible Adipogenic Activity and Can Also Differentiate Into Osteoblasts in a Perioxisome Proliferator-Activated Receptor-Mediated Fashion
Hah, Y., Joo, H.-H., Kang, Y., Park, B.-W., Hwang, S., Kim, J., Sung, I., Rho, G., Woo, D. K., & Byun, J. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.9611 · Cited by 14
Rosiglitazone inhibition of calvaria-derived osteoblast differentiation is through both of PPARγ and GPR40 and GSK3β-dependent pathway
Tang, X., Wang, C.-N., Zhu, X., & Ni, X. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.013 · Cited by 14
Glycemic Targets and Medication Limitations for Type 2 Diabetes Mellitus in the Older Adult
Thompson, A. M., Linnebur, S. A., Griend, J. P. V., & Saseen, J. J. (2014) · The Consultant Pharmacist · doi:10.4140/tcp.n.2014.110 · Cited by 15
CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation
Wyles, C. C., Paradise, C. R., Houdek, M. T., Slager, S. L., Terzic, A., Behfar, A., van Wijnen, A. J., & Sierra, R. J. (2019) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000713 · Cited by 14
Osteoporose und Multimorbidität
Wicklein, S., & Gosch, M. (2019) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-019-01569-5 · Cited by 14
Design and Synthesis of Benzimidazole-Linked meta-Substituted Benzylidenes/Benzyls as Biologically Significant New Chemical Entities
Verma, R. K., Mall, R., Ghosh, P., & Kumar, V. (2013) · Synthetic Communications · doi:10.1080/00397911.2012.678461 · Cited by 13
A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes
Truitt, K. E., Goldberg, R. B., Rosenstock, J., Chou, H. S., Merante, D., Triscari, J. M., & Wang, A. C. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003715079 · Cited by 13
Obesity and type 2 diabetes, not a diet high in fat, sucrose, and cholesterol, negatively impacts bone outcomes in the hyperphagic Otsuka Long Evans Tokushima Fatty rat
Ortinau, L. C., Linden, M. A., Dirkes, R. K., Rector, R. S., & Hinton, P. S. (2017) · Bone · doi:10.1016/j.bone.2017.09.003 · Cited by 13
Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease
Masajtis‐Zagajewska, A., Hołub, T., Pęczek, K., Makówka, A., & Nowicki, M. P. (2021) · Medicina · doi:10.3390/medicina57121352 · Cited by 13
Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management
Bode, B. W. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2055 · Cited by 12
Protein tyrosine phosphatase SHP-1 modulates osteoblast differentiation through direct association with and dephosphorylation of GSK3β
Tang, X., Wang, C.-N., Zhu, X., & Ni, X. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.08.048 · Cited by 13
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516
Lagu, B. R., Kluge, A. F., Goddeeris, M. M., Tozzo, E., Fredenburg, R. A., Chelur, S., Senaiar, R. S., Jaleel, M., Babu, D. R. K., Tiwari, N. K., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.006 · Cited by 13
Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 15
Lanreotide Therapy in Carcinoid Syndrome: Prospective Analysis of Patient-Reported Symptoms in Patients Responsive To Prior Octreotide Therapy And Patients Naïve To Somatostatin Analogue Therapy in The Elect Phase 3 Study
Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S. P., Mirakhur, B., Pommier, R. F., Shaheen, M. F., & Vinik, A. I. (2018) · Endocrine Practice · doi:10.4158/ep172000.or · Cited by 12
Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: A network meta-analysis
Tsai, W.-H., Kong, S.-K., Lin, C.-L., Cheng, K.-H., Cheng, Y.-T., Chien, M.-N., Lee, C., & Tsai, M.-C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110082 · Cited by 13
Histopathological Evaluation of Heart Toxicity of a Novel Selective PPAR-γ Agonists CKD-501 in db/db Mice
Yang, H.-I., Kim, W. S., Kim, D.-H., & Kang, J. S. (2013) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.101 · Cited by 12
Thiazolidinediones: Antidiabetic agents with effects on bone
Debiais, F. (2009) · Joint Bone Spine · doi:10.1016/j.jbspin.2009.01.005 · Cited by 12
Tolerability of Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes: Results from 6 Phase III Studies
Davidson, J. A. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.2.120 · Cited by 11
Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
Bethel, M. A., Xu, W., & Theodorakis, M. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12401 · Cited by 12
Fractures are increased and bisphosphonate use decreased in individuals with insulin-dependent diabetes: a 10 year cohort study
Fraser, L.-A., Παπαϊωάννου, Α., Adachi, J. D., Ma, J., & Thabane, L. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-201 · Cited by 11
Diabetes and Osteoporosis
Oh, K. W. (2009) · Korean Diabetes Journal · doi:10.4093/kdj.2009.33.3.169 · Cited by 11
PPARγ, an essential regulator of bone mass: Metabolic and molecular cues
Lecka‐Czernik, B. (2010) · IBMS BoneKEy · doi:10.1138/20100443 · Cited by 10
Effect of PPAR-γ Agonist Rosiglitazone on Bone Mineral Density and Serum Adipokines in C57BL/6 Male Mice
Broulik, P. D., Šefc, L., & Haluzı́k, M. (2011) · Folia Biologica · doi:10.14712/fb2011057040133 · Cited by 10
Antidiabetic effect of SN158 through PPARα/γ dual activation in ob/ob mice
Jung, Y., Cao, Y., Paudel, S., Yoon, G., Cheon, S. H., Bae, G., Jin, L. T., Kim, Y. K., & Kim, S. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.02.014 · Cited by 10
RANKL from Bone Marrow Adipose Lineage Cells Promotes Osteoclast Formation and Bone LossPreprint
Hu, Y., Li, X., Zhi, X., Cong, W., Huang, B., Chen, H., Wang, Y., Li, Y., Wang, L., Fang, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.12.294348 · Cited by 10
Different Forms of Regulated Cell Death in Type-2-Diabetes-Mellitus-Related Osteoporosis: A Focus on Mechanisms and Therapeutic Strategies
Li, C., Gong, H., Shi, P., Liu, S., & Zhang, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094417 · Cited by 10
Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites
Chen, N., Zhang, M., Shi, B., Luo, X., Huang, R., Luo, Z., He, J., Xue, S., Li, N., Ling, Z., et al. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.09.002 · Cited by 9
Peroxisome proliferator activated receptor γ promotes mineralization and differentiation in cementoblasts via inhibiting Wnt/β‐catenin signaling pathway
Hu, Y., Wang, C., Ha, S., Zhu, N., Cao, Z., & Song, Y. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29509 · Cited by 9
Update on: effects of anti-diabetic drugs on bone metabolism
Mabilleau, G., & Bouvard, B. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1831911 · Cited by 9
Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis
Kress, B. J., Kim, D. H., Mayo, J. R., Farris, J. T., Heck, B., Sarver, J. G., Andy, D., Trendel, J. A., Heck, B. E., & Erhardt, P. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00560 · Cited by 9
Glucose and Low-Density Lipoprotein Cholesterol Lowering in Elderly Patients with Type 2 Diabetes
Marrs, J. C. (2012) · Drugs & Aging · doi:10.2165/11599290-000000000-00000 · Cited by 9
Thiazolidinediones and bone fractures
Kaku, K., & Hashiramoto, M. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00142.x · Cited by 9
5-Androstene-3β,7β,17β-triol (β-AET) Slows Thermal Injury Induced Osteopenia in Mice: Relation to Aging and Osteoporosis
Malik, A. K., Khaldoyanidi, S. K., Auci, D. L., Miller, S. C., Ahlem, C. N., Reading, C. L., Page, T., & Frincke, J. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013566 · Cited by 9
Rosiglitazone induces adipogenesis of both marrow and periosteum derived mesenchymal stem cells during endochondral fracture healing
Mehta, D. D., Dankert, J. F., Yim, N. L., Leclerc, K., & Leucht, P. (2021) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2021.11.005 · Cited by 8
The effect of antidiabetic drugs on bone metabolism: a concise review
Psachna, S., Chondrogianni, M. E., Stathopoulos, K. D., Polymeris, A., Chatzigeorgiou, A., Chronopoulos, E., Tournis, S., & Kassi, E. N. (2024) · Endocrine · doi:10.1007/s12020-024-04070-1 · Cited by 8
Evidence‐based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease
Tuttle, K. R., & McGill, J. B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13986 · Cited by 8
The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes
Li, H., Cui, R., Cai, H., Guo-ting, W., Lv, Z., Sheng, C., Cheng, X., Li, F., & Yu, Y. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0104-4 · Cited by 8
Adopted orphans as regulators of inflammation, immunity and skeletal homeostasis
Ipseiz, N., Scholtysek, C., Culemann, S., & Krönke, G. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14055 · Cited by 8
Osteoporosis in patients with diabetes after kidney transplantation
Gosmanova, E. O., & Gosmanov, A. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9397-5 · Cited by 8
Impact of prescription drugs on second fragility fractures among US Medicare patients
Munson, J. C., Bynum, J., Bell, J., McDonough, C. M., Wang, Q., Tosteson, T. D., & Tosteson, A. N. A. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4697-0 · Cited by 8
The European Exenatide study of long‐term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics
KAZDA, C. M., Gallwitz, B., Simó, R., Guzmán, J. R., Kraus, P., Nicolay, C., Rose, L., & Schernthaner, G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01091.x · Cited by 8
Medication-induced fractures: Screening and treatment strategies
Javed, L., Khakwani, A. S., Khan, U., & Humphrey, M. B. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.08.024 · Cited by 7
Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint
Miller, C. G., Bogado, C. E., Nino, A., Northcutt, A. R., Yu, H. J., Lewiecki, E. M., Paul, G., Cobitz, A. R., Wooddell, M. J., Bilezikian, J. P., et al. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2016.02.003 · Cited by 7
Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.
Aoki, C., Suzuki, K., Kuroda, H., Sagara, M., Shimizu, M., Kasai, K., & Aso, Y. (2017) · PubMed Central · doi:10.18999/nagjms.79.1.9 · Cited by 7
A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
Ryang, S., Kim, S. S., Bae, J. C., Han, J. M., Kwon, S. K., Kim, Y. I., Nam‐Goong, I. S., Kim, E. S., Kim, M.-K., Lee, C. W., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14766 · Cited by 6
Diabetes melito, tiazolidinedionas e fraturas: uma história inacabada
da Silva, A. G., & Lazaretti‐Castro, M. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000400002 · Cited by 7
PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities
Perreault, M., Erbe, D. V., & Tobin, J. F. (2008) · PPAR Research · doi:10.1155/2008/125387 · Cited by 9
Clinical Update on Nursing Home Medicine: 2011
Messinger‐Rapport, B. J., Morley, J. E., Thomas, D. R., & Gammack, J. K. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.08.007 · Cited by 7
Regulation of brown adipose tissue recruitment, metabolism and thermogenic function by peroxisome proliferator-activated receptorγ
Lopes, A. B., Deshaies, Y., & Festuccia, W. T. (2015) · Temperature · doi:10.1080/23328940.2015.1011564 · Cited by 6
Diabetes, Bone Density, and Fractures
Shivaswamy, V. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s1-004 · Cited by 7
Urine-derived stem cell therapy for diabetes mellitus and its complications: progress and challenges
Zou, Y., Li, S., Chen, W., & Xu, J. (2023) · Endocrine · doi:10.1007/s12020-023-03552-y · Cited by 6
The Role of Gender in the Onset, Development and Impact of Type 2 Diabetes Mellitus and Its Co-Morbidities
Cassidy, F. C., Lafferty, S., & Coleman, C. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94271 · Cited by 5
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Clarke, B. L. (2010) · Yearbook of Medicine · doi:10.1016/s0084-3873(10)79794-7 · Cited by 6
Type 2 Diabetes and Bone Disease
López, N., Cohen, S. M., & Emanuele, M. (2023) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-023-09288-7 · Cited by 6
Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics
Fitzpatrick, L. A., Bilezikian, J. P., Wooddell, M. J., Paul, G., Kolatkar, N. S., Nino, A., Miller, C. G., Bogado, C. E., Arnaud, C. D., & Cobitz, A. R. (2011) · Journal of Drug Assessment · doi:10.3109/21556660.2011.641703 · Cited by 6
Emerging Therapeutic Approaches to Treat Dyslipidemia
Preiss, D., & Packard, C. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0506-3 · Cited by 6
Diabetes Medications and Bone
Grey, A. B. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0250-z · Cited by 6
Association between site‐specific bone mineral density and glucose homeostasis and anthropometric traits in healthy men and women
Kim, S., Cui, J., Rhyu, J., Guo, X., Chen, Y. I., Hsueh, W. A., Rotter, J. I., & Goodarzi, M. O. (2018) · Clinical Endocrinology · doi:10.1111/cen.13602 · Cited by 6
Drug-Induced Osteoporosis
Gasser, R. W., Kocijan, R., Zendeli, A., & Resch, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030993 · Cited by 5
Pharmacological Risk Assessment for Dental Implants
Wu, X., & Tamimi, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-71181-2_4 · Cited by 5
Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co‐administration in patients with type 2 diabetes mellitus
Ock, M., Lee, S., & Kim, H. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13640 · Cited by 5
Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH
Yazdi, Z. S., Streeten, E. A., Whitlatch, H. B., Montasser, M. E., Beitelshees, A. L., & Taylor, S. I. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad554 · Cited by 5
Drug Therapy of Elderly Diabetic Patients
Hong, E. G. (2011) · The Korean Journal of Internal Medicine · Cited by 5
Recomendaciones sobre el efecto de los fármacos antidiabéticos en el hueso
Rozas-Moreno, P., Reyes‐García, R., Jódar-Gimeno, E., Varsavsky, M., Luque-Fernández, I., Berdonces, M. C., & Muñoz‐Torres, M. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2016.11.001 · Cited by 5
Impact of Diabetes and its Treatment on Bone
Schwartz, A. V. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9049-3 · Cited by 5
Overcoming challenges in Type 2 diabetes management to improve patient outcomes
Brown, M. T., & LeRoith, D. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.45 · Cited by 5
A Randomized Controlled Trial on the Effect of Luseogliflozin on Bone Microarchitecture Evaluated Using HR-pQCT in Elderly Type 2 Diabetes
Shigeno, R., Horie, I., Haraguchi, A., Niimi, R., Chiba, K., Tashiro, S., Kawazoe, Y., Sato, S., Osaki, M., Kawakami, A., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01634-2 · Cited by 4
Effect of Fibroblast Growth Factor (FGF) 19 and 21 on Hip Geometry and Strength in Post-menopausal Osteoporosis (PMO)
Kim, E., Moore, A. E. B., Dulnoan, D., & Hampson, G. (2024) · Calcified Tissue International · doi:10.1007/s00223-024-01284-3 · Cited by 4
Uncovering mechanisms of thiazolidinediones on osteogenesis and adipogenesis using spatial fluxomics
Brejchová, K., Rahm, M., Beňová, A., Domanska, V., Reyes‐Gutierrez, P. E., Dzubanova, M., Trubacova, R., Vondráčková, M., Čajka, T., Tencerová, M., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156157 · Cited by 5
Cardiometabolic interventions – focus on transcriptional regulators
Chai, J. T., & Choudhury, R. P. (2013) · European Journal of Cardiovascular Medicine · doi:10.5083/ejcm.20424884.102 · Cited by 4
Clinical practice guidelines for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions
Reyes‐García, R., Gimeno, E. J., Martín, A. G., Muñoz, M. R., Sáez, J. M. G., Fernández, I. L., Varsavsky, M., Iglesias, S. G., Rodríguez, I. C., Ballesteros-Pomar, M. D., et al. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.01.004 · Cited by 4
Thiazolidinediones Inhibit Mouse Osteoblastic MC3T3-E1 Cell Proliferation in Part through the Wnt Signaling Pathway
Duan, M., Zhou, B., Zhou, X., & Yuan, G. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000191 · Cited by 4
Diabetes y osteoporosis: acción de las hormonas gastrointestinales sobre el hueso
García‐Martin, A., Reyes‐García, R., García-Castro, J. M., & Muñoz‐Torres, M. (2013) · Revista Clínica Española · doi:10.1016/j.rce.2013.01.014 · Cited by 4
Diabetes and osteoporosis: Action of gastrointestinal hormones on the bone
García‐Martin, A., Reyes‐García, R., García-Castro, J. M., & Muñoz‐Torres, M. (2013) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2013.05.004 · Cited by 5
Evaluation of type 2 diabetes mellitus medication management and control in older adults.
Thompson, A., Griend, J. V. V., Linnebur, S., & Saseen, J. (2013) · The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists · doi:10.4140/tcp.n.2013.296 · Cited by 4
Response: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J2012;36:371-8)
Song, S. O., Kim, K. J., & Lee, B. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.6.462 · Cited by 4
Withdrawal of pioglitazone in patients with type 2 diabetes mellitus
Iwase, M., Asano, T., Sasaki, N., Yoshizumi, H., Hiramatsu, S., Sakai, Y., Ogo, A., & Iida, M. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01109.x · Cited by 4
Pathogenesis of Osteoporosis
Billington, E. O., & Reid, I. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64552-x · Cited by 4

Authors: Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., Viberti, G., & for the A Diabetes Outcome Progression Trial (ADOPT) Study Group
Affiliations: University of Washington (US)
Mount Sinai Hospital (CA)
George Washington University (US)
The University of Texas at San Antonio Health Science Center (US)
University of Michigan (US)
Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
GlaxoSmithKline (United States) (US)
King's College London (GB)
ORCID: Kahn, Steven E.
Zinman, Bernard
Lachin, John M.
Herman, William H.
Holman, Rury R.
Yu, Dahong
Heise, Mark A.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2008-05-01
Volume: 31
Issue: 5
Pages: 845-851
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc07-2270
OpenAlex: W2099673402
Cited by: 537
References: 22
Citations by year: 2026: 7 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 17 · 2021: 30 · 2020: 18 · 2019: 19 · 2018: 36 · 2017: 31 · 2016: 31 · 2015: 31 · 2014: 40 · 2013: 43 · 2012: 41
FWCI: 39.37
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: GlaxoSmithKline
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: rosiglitazone, fracture, type 2 diabetes, ADOPT trial, metformin, glibenclamide, sex differences, women, fracture risk factors, bone fragility, thiazolidinediones
MeSH terms: Rosiglitazone, Aged, Diabetes Mellitus, Type 2, Female, Glyburide, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Treatment Outcome, Age of Onset, Disease Progression, Thiazolidinediones, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rosiglitazone-Associated Fractures in Type 2 Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks